Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill

Jagannadha Avasarala
  • Drug Target Insights, January 2017, SAGE Publications
  • DOI: 10.1177/1177392817737515

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1177/1177392817737515

The following have contributed to this page: Dr Jagannadha R Avasarala